Online inquiry

IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12434MR)

This product GTTS-WQ12434MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNG gene. The antibody can be applied in Hemophagocytic lymphohistiocytosis (HLH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000619.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3458
UniProt ID P01579
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12434MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2051MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ711MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ2102MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ6316MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ10826MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ11354MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ8935MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ2356MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AME-133v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW